140 related articles for article (PubMed ID: 18426243)
1. Strategic biopharmaceutical portfolio development: an analysis of constraint-induced implications.
George ED; Farid SS
Biotechnol Prog; 2008; 24(3):698-713. PubMed ID: 18426243
[TBL] [Abstract][Full Text] [Related]
2. Multiobjective long-term planning of biopharmaceutical manufacturing facilities.
Lakhdar K; Savery J; Papageorgiou LG; Farid SS
Biotechnol Prog; 2007; 23(6):1383-93. PubMed ID: 17924645
[TBL] [Abstract][Full Text] [Related]
3. Capacity planning for batch and perfusion bioprocesses across multiple biopharmaceutical facilities.
Siganporia CC; Ghosh S; Daszkowski T; Papageorgiou LG; Farid SS
Biotechnol Prog; 2014; 30(3):594-606. PubMed ID: 24376262
[TBL] [Abstract][Full Text] [Related]
4. Decision-making in product portfolios of pharmaceutical research and development--managing streams of innovation in highly regulated markets.
Jekunen A
Drug Des Devel Ther; 2014; 8():2009-16. PubMed ID: 25364229
[TBL] [Abstract][Full Text] [Related]
5. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
Farid SS; Baron M; Stamatis C; Nie W; Coffman J
MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
[TBL] [Abstract][Full Text] [Related]
6. Strategy as a portfolio of real options.
Luehrman TA
Harv Bus Rev; 1998; 76(5):89-99, 187. PubMed ID: 10185434
[TBL] [Abstract][Full Text] [Related]
7. Dynamic Portfolio Strategy Using Clustering Approach.
Ren F; Lu YN; Li SP; Jiang XF; Zhong LX; Qiu T
PLoS One; 2017; 12(1):e0169299. PubMed ID: 28129333
[TBL] [Abstract][Full Text] [Related]
8. Securitization of a Drug Development Mega-Fund: The Time-Certain Research-Backed Obligation.
Ortiz CE; Stone CA; Zissu A
Pharmaceut Med; 2020 Jun; 34(3):167-173. PubMed ID: 32266695
[TBL] [Abstract][Full Text] [Related]
9. Prioritizing investments in rapid response vaccine technologies for emerging infections: A portfolio decision analysis.
Gouglas D; Marsh K
PLoS One; 2021; 16(2):e0246235. PubMed ID: 33571206
[TBL] [Abstract][Full Text] [Related]
10. How development and manufacturing will need to be structured--heads of development/manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Nepveux K; Sherlock JP; Futran M; Thien M; Krumme M
J Pharm Sci; 2015 Mar; 104(3):850-64. PubMed ID: 25630721
[TBL] [Abstract][Full Text] [Related]
11. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
[TBL] [Abstract][Full Text] [Related]
12. A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk.
Patel NR; Ankolekar S; Antonijevic Z; Rajicic N
Stat Med; 2013 May; 32(10):1763-77. PubMed ID: 23300097
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical portfolio management: global disease burden and corporate performance metrics.
Daems R; Maes E; Mehra M; Carroll B; Thomas A
Value Health; 2014 Sep; 17(6):732-8. PubMed ID: 25236997
[TBL] [Abstract][Full Text] [Related]
14. Strategic funding priorities in the pharmaceutical sciences allied to Quality by Design (QbD) and Process Analytical Technology (PAT).
Aksu B; De Beer T; Folestad S; Ketolainen J; Lindén H; Lopes JA; de Matas M; Oostra W; Rantanen J; Weimer M
Eur J Pharm Sci; 2012 Sep; 47(2):402-5. PubMed ID: 22749874
[TBL] [Abstract][Full Text] [Related]
15. Recombinant drug development, regulation, and commercialization: an Indian industry perspective.
Sahoo N; Manchikanti P
BioDrugs; 2011 Apr; 25(2):105-13. PubMed ID: 21230010
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Adaptive Design on Portfolio Optimization.
Antonijevic Z
Ther Innov Regul Sci; 2016 Sep; 50(5):615-619. PubMed ID: 30231754
[TBL] [Abstract][Full Text] [Related]
17. Biopharmaceutical benchmarks--2003.
Walsh G
Nat Biotechnol; 2003 Aug; 21(8):865-70. PubMed ID: 12894198
[No Abstract] [Full Text] [Related]
18. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs.
Patel NR; Ankolekar S
Stat Med; 2007 Nov; 26(27):4976-88. PubMed ID: 17579924
[TBL] [Abstract][Full Text] [Related]
20. Integrating internal and external bioanalytical support to deliver a diversified pharmaceutical portfolio.
Summerfield SG; Evans C; Spooner N; Dunn JA; Szapacs ME; Yang E
Bioanalysis; 2014 May; 6(10):1311-9. PubMed ID: 24958115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
